New England Research & Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $472K | Buy |
+1,060
| New | +$472K | 0.22% | 109 |
|
|
2024
Q4 | – | Sell |
-4,575
| Closed | -$2.13M | – | 181 |
|
|
2024
Q3 | $2.13M | Buy |
4,575
+1,840
| +67% | +$856K | 1% | 32 |
|
|
2024
Q2 | $1.28M | Sell |
2,735
-100
| -4% | -$46.9K | 0.62% | 60 |
|
|
2024
Q1 | $1.19M | Buy |
+2,835
| New | +$1.19M | 0.58% | 58 |
|
|
2023
Q2 | – | Sell |
-2,475
| Closed | -$780K | – | 160 |
|
|
2023
Q1 | $780K | Buy |
2,475
+1,525
| +161% | +$481K | 0.46% | 80 |
|
|
2022
Q4 | $274K | Buy |
+950
| New | +$274K | 0.16% | 135 |
|
|
2019
Q4 | – | Sell |
-2,725
| Closed | -$462K | – | 161 |
|
|
2019
Q3 | $462K | Buy |
2,725
+375
| +16% | +$63.6K | 0.33% | 106 |
|
|
2019
Q2 | $431K | Buy |
2,350
+1,100
| +88% | +$202K | 0.29% | 113 |
|
|
2019
Q1 | $230K | Buy |
+1,250
| New | +$230K | 0.16% | 154 |
|